MYO1F

Across TCGA pan-cancer cohorts, MYO1F Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated MYO1F data layer compared with 23 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher MYO1F Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MYO1F expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

ACC, UCEC, and ESCA are the cancer types where MYO1F Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	OS	Median	All	0.145	0.888	<.001	45	view →
UCEC	DFS	Median	All	0.827	0.624	.004	16	view →
ESCA	DFS	Median	All	0.187	0.543	.003	12	view →
SKCM	OS	Median	All	0.959	0.862	.013	9	view →
SARC	DFS	Median	All	0.176	0.614	.003	6	view →
HNSC	DFS	Median	All	1.000	0.689	.025	4	view →
LGG	DFS	Median	All	0.494	0.827	.013	3	view →
COAD	OS	Median	III,IV	0.168	0.692	.043	3	view →
SCLC	DFS	Median	All	1.000	0.270	.038	2	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

MYO1F–ACC (OS)

Open the ACC breakdown →